SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma.
Bin LiMei-Yu RenYu-Zhen ChenYu-Qi MengTie-Niu SongZhi-Peng SuBo YangPublished in: The journal of gene medicine (2022)
SYNGR2 may be used as a biomarker for determining prognosis and immune infiltration in ESCC.
Keyphrases